PRPO Quote, Financials, Valuation and Earnings

Bio-Rad Laboratories, Inc. has a net margin of -1.17% compared to Precipio, Inc.'s net margin of -52.36%. Precipio, Inc.'s return on equity of -10.15% beat Bio-Rad Laboratories, Inc.'s return on equity of -9.77%.

Precipio, Inc. has a consensus price target of --, signalling downside risk potential of -10.25%. On the other hand Bio-Rad Laboratories, Inc. has an analysts' consensus of $348.00 which suggests that it could grow by 16.02%. Given that Bio-Rad Laboratories, Inc. has higher upside potential than Precipio, Inc., analysts believe Bio-Rad Laboratories, Inc. is more attractive than Precipio, Inc..

Precipio, Inc. has a beta of 1.198, which suggesting that the stock is 19.803% more volatile than S&P 500. In comparison Bio-Rad Laboratories, Inc. has a beta of 1.180, suggesting its more volatile than the S&P 500 by 18.018%.

Precipio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bio-Rad Laboratories, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Precipio, Inc. pays -- of its earnings as a dividend. Bio-Rad Laboratories, Inc. pays out -- of its earnings as a dividend.

Precipio, Inc. quarterly revenues are $6.8M, which are smaller than Bio-Rad Laboratories, Inc. quarterly revenues of $653M. Precipio, Inc.'s net income of -$79K is higher than Bio-Rad Laboratories, Inc.'s net income of -$341.9M. Notably, Precipio, Inc.'s price-to-earnings ratio is -- while Bio-Rad Laboratories, Inc.'s PE ratio is 27.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Precipio, Inc. is 1.45x versus 3.23x for Bio-Rad Laboratories, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Bionano Genomics, Inc. has a net margin of -1.17% compared to Precipio, Inc.'s net margin of -115.42%. Precipio, Inc.'s return on equity of -10.15% beat Bionano Genomics, Inc.'s return on equity of -84.77%.

Precipio, Inc. has a consensus price target of --, signalling downside risk potential of -10.25%. On the other hand Bionano Genomics, Inc. has an analysts' consensus of $7.50 which suggests that it could grow by 541.03%. Given that Bionano Genomics, Inc. has higher upside potential than Precipio, Inc., analysts believe Bionano Genomics, Inc. is more attractive than Precipio, Inc..

Precipio, Inc. has a beta of 1.198, which suggesting that the stock is 19.803% more volatile than S&P 500. In comparison Bionano Genomics, Inc. has a beta of 1.683, suggesting its more volatile than the S&P 500 by 68.319%.

Precipio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bionano Genomics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Precipio, Inc. pays -- of its earnings as a dividend. Bionano Genomics, Inc. pays out -- of its earnings as a dividend.

Precipio, Inc. quarterly revenues are $6.8M, which are smaller than Bionano Genomics, Inc. quarterly revenues of $7.4M. Precipio, Inc.'s net income of -$79K is higher than Bionano Genomics, Inc.'s net income of -$8.5M. Notably, Precipio, Inc.'s price-to-earnings ratio is -- while Bionano Genomics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Precipio, Inc. is 1.45x versus 0.14x for Bionano Genomics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Bruker Corp. has a net margin of -1.17% compared to Precipio, Inc.'s net margin of -6.8%. Precipio, Inc.'s return on equity of -10.15% beat Bruker Corp.'s return on equity of -1.2%.

Precipio, Inc. has a consensus price target of --, signalling downside risk potential of -10.25%. On the other hand Bruker Corp. has an analysts' consensus of $54.43 which suggests that it could grow by 30.9%. Given that Bruker Corp. has higher upside potential than Precipio, Inc., analysts believe Bruker Corp. is more attractive than Precipio, Inc..

Precipio, Inc. has a beta of 1.198, which suggesting that the stock is 19.803% more volatile than S&P 500. In comparison Bruker Corp. has a beta of 1.186, suggesting its more volatile than the S&P 500 by 18.621%.

Precipio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker Corp. offers a yield of 0.48% to investors and pays a quarterly dividend of $0.05 per share. Precipio, Inc. pays -- of its earnings as a dividend. Bruker Corp. pays out 26.44% of its earnings as a dividend. Bruker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Precipio, Inc. quarterly revenues are $6.8M, which are smaller than Bruker Corp. quarterly revenues of $860.5M. Precipio, Inc.'s net income of -$79K is higher than Bruker Corp.'s net income of -$58.5M. Notably, Precipio, Inc.'s price-to-earnings ratio is -- while Bruker Corp.'s PE ratio is 77.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Precipio, Inc. is 1.45x versus 1.84x for Bruker Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Harvard Bioscience, Inc. has a net margin of -1.17% compared to Precipio, Inc.'s net margin of -5.98%. Precipio, Inc.'s return on equity of -10.15% beat Harvard Bioscience, Inc.'s return on equity of -155.33%.

Precipio, Inc. has a consensus price target of --, signalling downside risk potential of -10.25%. On the other hand Harvard Bioscience, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 232.78%. Given that Harvard Bioscience, Inc. has higher upside potential than Precipio, Inc., analysts believe Harvard Bioscience, Inc. is more attractive than Precipio, Inc..

Precipio, Inc. has a beta of 1.198, which suggesting that the stock is 19.803% more volatile than S&P 500. In comparison Harvard Bioscience, Inc. has a beta of 1.548, suggesting its more volatile than the S&P 500 by 54.788%.

Precipio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harvard Bioscience, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Precipio, Inc. pays -- of its earnings as a dividend. Harvard Bioscience, Inc. pays out -- of its earnings as a dividend.

Precipio, Inc. quarterly revenues are $6.8M, which are smaller than Harvard Bioscience, Inc. quarterly revenues of $20.6M. Precipio, Inc.'s net income of -$79K is higher than Harvard Bioscience, Inc.'s net income of -$1.2M. Notably, Precipio, Inc.'s price-to-earnings ratio is -- while Harvard Bioscience, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Precipio, Inc. is 1.45x versus 0.31x for Harvard Bioscience, Inc.. Usually stocks with elevated PS ratios are considered overvalued.